ClinicalTrials.gg
CompletedNCT05178888Updated Feb 11, 2025

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

A Phase 1 interventional study of MRTX849 and Palbociclib in Advanced Solid Tumor, sponsored by Mirati Therapeutics Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation.

Read the detailed description

This study will evaluate the pharmacokinetics and preliminary clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and palbociclib is a small molecule inhibitor of CDK 4 and 6.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Mirati Therapeutics Inc. is the lead sponsor of 51 studies on the registry; 3 are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 4 (20%) have results posted.

First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of a solid tumor with KRAS G12C mutation
  • Unresectable or disease.
  • No available treatment with curative intent
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • History of significant toxicity on prior KRAS G12C or CDK4/6 inhibitor therapies
  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter the absorption of study treatment or result in an inability to swallow
  • Other active cancer
  • Cardiac abnormalities
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Dose escalation of MRTX849 and palbociclib to determine maximum tolerated dose in combination.

    Drug: MRTX849 · Drug: Palbociclib

  • Experimental
    Dose Expansion

    Expansion cohorts may be implemented to ensure sufficient safety experience, pharmacokinetic data and early evidence of clinical activity of MRTX in combination with palbociclib.

    Drug: MRTX849 · Drug: Palbociclib

Interventions

  • KRAS G12C inhibitor

    Also known as: KRAS G12C, adagrasib

  • CDK 4 and 6 inhibitor

    Also known as: IBRANCE

06

What researchers measure

Primary outcomes

  1. Characterize the number of patients with treatment emergent adverse events of the combination regimen in patients with advanced solid tumor malignancies with KRAS G12C mutation.

    Number of participants with treatment emergent adverse events

    Time frame: 24 months

  2. Evaluate Pharmacokinetics of the combination regimen

    Plasma concentration

    Time frame: 24 months

  3. Establish Maximum Tolerated Dose

    Number of patients with dose limiting toxicity

    Time frame: 24 months

  4. Evaluate preliminary clinical activity of the combination regimen

    Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)

    Time frame: 24 months

07

Study locations

4 sites
  • Local Institution - 804
    Orlando, Florida 32827, United States
  • Local Institution - 803
    Nashville, Tennessee 37203, United States
  • Local Institution - 802
    Houston, Texas 77030, United States
  • Local Institution - 801
    San Antonio, Texas 78229, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Jun 2023, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2021
First posted
Jan 5, 2022
StartActual
Jan 20, 2022
Primary completionActual
Jun 15, 2023
CompletionActual
Dec 30, 2024
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05178888
Responsible party
Sponsor
First posted
Jan 5, 2022
Start date
Jan 20, 2022
Primary completion
Jun 15, 2023
Completion
Dec 30, 2024
Last update
Feb 11, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adagrasib

Start the discussion